Bicycle Therapeutics plc / Fundamentals
Income statement
- Net revenue
€16.64M - Cost of goods sold
€3.38M - Gross profit
€13.26M - SG&A expenses
€68.56M - R&D expenses
€196.88M - EBITDA
-€224.41M - D&A
-€2.35M - EBIT
-€248.83M - Interest expenses
€119.96K - EBT
-€214.21M - Tax expenses
-€5.05M - Net income
-€209.17M
Cash flow statement
- Net deferred tax
-€5.19M - Non-cash items
-€32.09M - Changes in working capital
€27.56M - Operating cash flow
-€179.78M - Capex
€1.64M - Other investing cash flow
€0.00 - Net investing cash flow
-€1.64M - Total cash dividends paid
€0.00 - Issuance of common stock
-€472.06M - Debt repayment
-€27.70M - Other financing cash flow
€2.81M - Net financing cash flow
-€27.46M - Foreign exchange effects
€1.89M - Net change in cash
-€206.58M - Cash at end of period
€623.11M - Free cash flow
-€178.14M
Balance sheet
- Cash and cash equivalents
€622.64M - Cash and short-term investments
€622.64M - Total receivables
€52.43M - Inventory
€0.00 - Other current assets
€19.04M - Total current assets
€694.11M - Property, plant & equipment
€12.18M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€472.08K - Other non-current assets
€11.45M - Total non-current assets
€24.10M - Total assets
€718.20M - Accounts payable
€15.76M - Short-term debt
€9.38M - Other current liabilities
€29.06M - Total current liabilities
€66.82M - Long-term debt
€1.52M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€983.00K - Total non-current liabilities
€74.09M - Total liabilities
€140.91M - Common stock
€770.69K - Retained earnings
-€708.12M - Other equity
-€2.90M - Total equity
€577.30M - Total liabilities and shareholders' equity
€718.20M
Company information
- Market capitalization
€427.35M - Employees
305 - Enterprise Value
-€178.44M
Company ratios
- Gross margin
-
79.7% Much better than peer group: -482.5% - EBITDA margin
-
-1,348.6% Much better than peer group: -5,650.2% - EBIT margin
-
-1,495.3% Much better than peer group: -15,812.0% - EBT margin
-
-1,287.3% Much better than peer group: -5,082.7% - Net margin
-
-1,257.0% Much better than peer group: -4,826.5% - ROE
-
-36.2% Much better than peer group: -104.5% - ROA
-
-29.1% Even with peer group: -29.0% - Asset turnover
-
2.3% Even with peer group: 5.5% - FCF margin
-
-1,090.3% Much better than peer group: -11,658.5% - FCF yield
-42.5% - Efficiency ratio
1,448.6% - Net sales per employee
-
€54.56K - Net income per employee
-
-€685.79K